4.6 Review

Precision medicine in diabetic nephropathy and chronic kidney disease

期刊

NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 36, 期 -, 页码 10-13

出版社

OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfaa380

关键词

albuminuria; chronic kidney disease; Dickkopf 3; precision medicine; progression

资金

  1. Amicus Therapeutics UK Limited
  2. Boehringer Ingelheim RCV GmbH Co KG
  3. Astellas Pharma
  4. Vifor Pharma Osterreich GmbH
  5. European Union [848011]

向作者/读者索取更多资源

Progressive chronic kidney disease in individuals with type 2 diabetes mellitus is a global public health issue with challenges in predicting the individual course of the disease progression. Patterns of progression in CKD patients include both linear and nonlinear trajectories of GFR loss, with kidney function potentially remaining stable for years in the elderly.
Progressive chronic kidney disease (CKD) in individuals with type 2 diabetes mellitus is a global public health problem accompanied by substantial comorbidities and reduced life expectancy. In this respect, CKD leading to uremia can be seen as a systemic disease with a critical impact on virtually all organ systems. Thus it is of particular importance to identify patients with incipient CKD and ongoing CKD progression, but the individual course of CKD is challenging to predict. Patterns of progression in persons with CKD include linear and nonlinear trajectories of glomerular filtration rate (GFR) loss. Kidney function can also remain stable for years, especially in the elderly. In particular, one-fifth of individuals show a substantial GFR decline in the absence of high albuminuria (nonproteinuric CKD), rendering albuminuria less suitable for predicting the progression in such individuals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据